HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant Includes OTCs In Bid For Dramatic Growth By 2013

This article was originally published in The Tan Sheet

Executive Summary

The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.

You may also be interested in...

In Brief

Valeant acquires iNova, closes Afexa deal; CRN says FDA’s proposed rule on gifts “goes too far”; Kentucky bill would strengthen PSE limits; and more OTC drug and nutritional product market news In Brief

Valeant Deal Would Aid Afexa’s Cold-FX Expansion Plans

Valeant Pharmaceuticals International’s acquisition of Afexa Health Sciences likely will boost efforts to transition Afexa’s Cold-FX from a Canadian natural health product to a U.S. pharmaceutical.

NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building

NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts